AJMC® in the Press: March 6, 2026 News & Updates

The American Journal of Managed Care (AJMC) highlighted several key developments in healthcare news and research on March 6, 2026, signaling ongoing progress and emerging challenges across a range of medical specialties. Coverage included updates on cancer treatments, HIV research, and emerging therapies for conditions like alopecia areata and transthyretin amyloid cardiomyopathy (ATTR-CM). This digest of recent findings reflects a dynamic period for managed care, with a focus on improving patient outcomes and navigating complex policy landscapes.

Cutaneous Squamous Cell Carcinoma Treatment Advances

Recent research indicates that PD-1 and PD-L1 agents are showing improved outcomes for patients with cutaneous squamous cell carcinoma (CSCC). Dr. Todd Schlesinger’s work, as reported by AJMC, suggests these immunotherapies are proving effective. These agents work by blocking proteins that prevent the immune system from attacking cancer cells, essentially “releasing the brakes” on the body’s natural defenses. AJMC’s coverage notes this is a significant step forward in treating this type of skin cancer. It’s important to understand that although promising, the specific details of Dr. Schlesinger’s study – including sample size, patient demographics, and long-term follow-up data – would be found in the full publication, which wasn’t provided in the source material.

Breakthroughs and Future Directions in HIV Research

The Conference on Retroviruses and Opportunistic Infections (CROI) 2026, a major event in HIV research, was celebrated for its progress and forward-looking discussions. AJMC reported that leading HIV researchers reflected on breakthroughs and identified ongoing challenges. Specifically, the postpartum period was highlighted as a critical gap in HIV care, with Elona Toska, MSc, DPhil, emphasizing the need for improved support during this time. This underscores the importance of continuous care and addressing specific vulnerabilities within the HIV-positive population. Further details on CROI 2026 are available through AJMC.

Emerging Therapies and Clinical Data

Several other areas saw notable developments. Intralesional cemiplimab showed promise as a non-surgical alternative for early-stage CSCC, offering a potentially less invasive treatment option. Modern clinical data highlighted the potential of povorcitinib to achieve high-threshold lesion clearance in hidradenitis suppurativa (HS), a chronic inflammatory skin condition. Ruxolitinib cream also demonstrated strong efficacy and a reassuring safety profile in new analyses. These findings suggest a growing arsenal of targeted therapies for dermatological conditions.

Psoriatic Disease Treatment Choices

Philip Mease, MD, discussed how to choose between biologic and oral therapies for psoriatic disease. This highlights the increasing complexity of treatment decisions, requiring clinicians to carefully consider individual patient factors and the latest evidence. The choice between these therapies often depends on disease severity, patient preferences, and potential side effects. AJMC’s coverage of this topic emphasizes the need for personalized medicine approaches.

Policy and System Pressures

Beyond clinical advancements, AJMC’s reporting on March 6, 2026, also touched on broader systemic issues. A webinar featuring experts warned of pressures on the healthcare system, stemming from factors like the Medicare For All (MFN) proposals and the Inflation Reduction Act (IRA). These policy changes are expected to have significant implications for drug pricing, access to care, and the financial stability of healthcare providers. The interplay between policy and clinical practice is a recurring theme in managed care, requiring ongoing adaptation and strategic planning.

CDK4/6 Inhibitors in Advanced Breast Cancer: Timing Considerations

The question of whether earlier intervention with CDK4/6 inhibitors in advanced breast cancer is truly “better” was also addressed. These inhibitors target specific proteins involved in cancer cell growth and proliferation. The debate centers on whether initiating treatment sooner, rather than later, leads to improved outcomes. This is an area of active research, with ongoing clinical trials seeking to clarify the optimal treatment strategy.

What’s on the Horizon for Managed Care

The developments highlighted by AJMC on March 6, 2026, point to several key trends shaping the future of managed care. These include a growing emphasis on personalized medicine, the integration of new technologies, and the need to address systemic challenges related to cost and access. Ongoing research and policy debates will continue to drive innovation and shape the landscape of healthcare delivery. The American Journal of Managed Care will likely continue to provide critical insights into these evolving dynamics. You can find more information on AJMC’s website, including details on upcoming conferences and publications. Further monitoring of clinical trial results and policy changes will be essential for healthcare professionals and patients alike. The AJMC conference page lists upcoming events where these topics will be discussed in greater detail.

Staying Informed: Patients should always discuss treatment options and potential risks with their healthcare providers. Public health organizations, such as the Centers for Disease Control and Prevention (CDC), offer reliable information on various health conditions and preventative measures.